Those tools commonly integrated patients’ clinicopathological traits including patient’s age, tumor size, histologic grade, LVI, ER, PR, HER2, Ki67 index and the number of SLNs + to evaluate the likelihood of non-SLNs metastasis, but they used a limited number of cases and lacked external validation (22, 36). Here, ERBB2 is linked to neoplasm.